StemSynergy Therapeutics (SSTI) is a biotechnology company dedicated to developing innovative therapeutics that specifically target critical signaling pathways involved in cancer, namely Wnt, Notch, and Myc. By focusing on these fundamental mechanisms, SSTI aims to identify drug targets that not only enhance therapeutic efficacy but also minimize toxicity. The company has made significant strides in its research, holding one awarded patent and three pending patents for its novel technologies. SSTI's preclinical pipeline is robust, featuring six promising therapeutic agents that leverage a multi-faceted scientific approach to address significant unmet needs in cancer treatment.

The technologies developed by SSTI include potent modulators of the Wnt and Notch signaling pathways, which have shown the potential to reduce tumor burden in vivo. These compounds are positioned as first-in-class agents due to their unique mechanisms of action and cellular targets. Additionally, SSTI is advancing its Familial Adenomatous Polyposis (FAP) Program, further expanding its portfolio of breakthrough technologies. With patent protection on multiple lead compounds, SSTI is well-equipped to contribute to the evolving landscape of cancer therapeutics.

United States

StemSynergy Therapeutics, Inc. (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer. We target the cancer stem/initiating cell (CSC) populations, with the overall aim of eliminating tumor growth. We have two patents awarded and one patent pending for breakthrough technologies in modulating cancer stem cell pathways, such as those driven by Wnt, Notch, and Sonic Hedgehog (Shh) signaling. With a multi-pronged scientific approach and a number of agents targeting these pathways, SSTI is well positioned to address critical unmet needs in cancer treatment.

StemSynergy Therapeutics

Company Details